# ALLIANCE: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve

Study · id `cardio:ct-nct05172960` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05172960](<https://clinicaltrials.gov/study/NCT05172960>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05172960

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1234 participants.

## Technical summary

Registry record NCT05172960. Non-randomized; no masking; primary purpose treatment. Start 2022-06-20 (actual); primary completion 2027-07 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 1234 participants (planned count; ClinicalTrials.gov record NCT05172960, source copy `cardio:ctgov-nct05172960-2026-09-24`, retrieved 2026-10-26)
- Started: 2022-06-20 (actual) (ClinicalTrials.gov record NCT05172960, source copy `cardio:ctgov-nct05172960-2026-09-24`, retrieved 2026-10-26)
- Primary completion: 2027-07 (anticipated) (ClinicalTrials.gov record NCT05172960, source copy `cardio:ctgov-nct05172960-2026-09-24`, retrieved 2026-10-26)
- Completion: 2037-01 (anticipated) (ClinicalTrials.gov record NCT05172960, source copy `cardio:ctgov-nct05172960-2026-09-24`, retrieved 2026-10-26)
- Countries: United States; Australia; Canada; New Zealand (ClinicalTrials.gov record NCT05172960, source copy `cardio:ctgov-nct05172960-2026-09-24`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05172960-2026-09-24`, retrieved 2026-10-26)

## The registry's words

- Brief title: ALLIANCE: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve
- Condition: Aortic Stenosis, Severe
- Intervention (Device): SAPIEN X4 THV
- Intervention (Device): SAPIEN X4S
- Lead sponsor: Edwards Lifesciences
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Aortic stenosis (`cardio:aortic-stenosis`)
- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry lists this organization as the lead sponsor: Edwards Lifesciences (`cardio:edwards-lifesciences`)

## Provenance

Content hash: f1ca350104882538da210640f0a9577e478b969a3cd5a7e0738decd330abba14
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
